| Literature DB >> 32454186 |
Ali Haydar1, Kevin Bryan Lo2, Abhinav Goyal3, Fahad Gul2, Eric Peterson2, Ruchika Bhargav2, Robert DeJoy2, Grace Salacup2, Jerald Pelayo2, Jeri Albano2, Zurab Azmaiparashvili2, Huma Ansari4, Gabriel Patarroyo Aponte5.
Abstract
BACKGROUND: As health-care institutions mobilize resources to address the coronavirus disease 2019 (COVID-19) pandemic, palliative care may potentially be underutilized. It is important to assess the use of palliative care in response to the COVID-19 pandemic.Entities:
Keywords: COVID-19; novel coronavirus; palliative care; underserved population
Mesh:
Year: 2020 PMID: 32454186 PMCID: PMC7255219 DOI: 10.1016/j.jpainsymman.2020.05.022
Source DB: PubMed Journal: J Pain Symptom Manage ISSN: 0885-3924 Impact factor: 3.612
Demographic and Clinical Characteristics of Patients
| Characteristics | Palliative Care ( | No Palliative Care ( | |
|---|---|---|---|
| Age median (IQR) | 74.76 ± 10.03 | 64.25 ± 14.95 | <0.0001 |
| Female gender, % (n) | 54 (21) | 50 (101) | 0.734 |
| Ethnicity, % (n) | 0.298 | ||
| African American | 63 (26) | 72 (145) | |
| Caucasian | 22 (9) | 4 (8) | |
| Hispanic | 5 (2) | 12 (24) | |
| Other | 10 (4) | 12 (24) | |
| Comorbidities, % (n) | |||
| BMI (mean ± SD) | 26.92 ± 8.84 | 29.89 ± 9.23 | 0.067 |
| COPD | 12 (5) | 12 (24) | 1.000 |
| Asthma | 2 (1) | 9 (18) | 0.324 |
| Heart failure | 10 (4) | 15 (30) | 0.467 |
| Atrial fibrillation | 20 (8) | 8 (16) | 0.04 |
| Liver cirrhosis | 5 (2) | 3 (6) | 0.626 |
| Diabetes | 49 (20) | 49 (98) | 1.000 |
| Chronic kidney disease | 23 (9) | 17 (34) | 0.374 |
| End-stage renal disease on dialysis | 7 (3) | 8 (16) | 1.000 |
| Coronary artery disease | 17 (7) | 19 (38) | 1.000 |
| Hypertension | 73 (30) | 75 (151) | 0.846 |
| Obesity | 34 (14) | 41 (82) | 0.485 |
| HIV | 2 (1) | 3 (6) | 1.000 |
| History of active cancer | 15 (6) | 10 (20) | 0.406 |
| Active cancer | 7 (3) | 2 (4) | 0.633 |
| FiO2% requirement on admission | 59.15 ± 35.14 | 34.87 ± 24.67 | <0.0001 |
| Serum ferritin on admission | 1848 ± 2225 | 1900 ± 3006 | 0.922 |
| D-dimer on admission | 7317 ± 2800 | 9581 ± 4143 | 0.014 |
| CRP on admission | 195 ± 126 | 127 ± 108 | 0.009 |
| Procalcitonin on admission | 4.33 ± 8.71 | 1.64 ± 6.53 | 0.142 |
| COVID-19 treatment | |||
| Hydroxychloroquine | 81 (33) | 56 (113) | 0.003 |
| Steroids | 46 (19) | 18 (36) | <0.0001 |
| Tocilizumab | 22 (9) | 6 (12) | 0.003 |
| Clinical outcomes | |||
| Inpatient death | 66 (27) | 12 (24) | <0.0001 |
| Need for CRRT/HD | 17 (7) | 9 (18) | 0.146 |
| Need for vasopressors | 61 (25) | 12 (24) | <0.0001 |
| Need for intubation | 61 (25) | 14 (28) | <0.0001 |
| Hospice/withdrawal of care | 59 (24) | 6 (12) | <0.0001 |
BMI = body mass index; COPD = chronic obstructive pulmonary disease; COVID-19 = coronavirus disease 2019; CRP = C-reactive protein; CRRT = continuous renal replacement therapy; HD = hemodialysis; IQR = interquartile range; SD = standard deviation.